Citadel Advisors
SPRY icon

Citadel Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Citadel Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
14,900
+200
+1% +$1.72K ﹤0.01% 12539
2026
Q1 		$118K Sell
14,700
-54,900
-79% -$526K ﹤0.01% 11868
2025
Q4 		$811K Sell
69,600
-58,700
-46% -$571K ﹤0.01% 7886
2025
Q3 		$1.29M Buy
128,300
+29,600
+30% +$425K ﹤0.01% 6989
2025
Q2 		$1.72M Sell
98,700
-43,900
-31% -$633K ﹤0.01% 5989
2025
Q1 		$1.79M Sell
142,600
-87,900
-38% -$1.06M ﹤0.01% 5739
2024
Q4 		$2.43M Buy
230,500
+69,300
+43% +$971K ﹤0.01% 5228
2024
Q3 		$2.34M Buy
161,200
+111,000
+221% +$1.32M ﹤0.01% 5240
2024
Q2 		$427K Buy
50,200
+8,200
+20% +$72.8K ﹤0.01% 8381
2024
Q1 		$429K Sell
42,000
-12,700
-23% -$94.7K ﹤0.01% 8717
2023
Q4 		$300K Sell
54,700
-60,900
-53% -$267K ﹤0.01% 9154
2023
Q3 		$437K Buy
115,600
+92,400
+398% +$607K ﹤0.01% 8364
2023
Q2 		$155K Buy
23,200
+21,000
+955% +$140K ﹤0.01% 10288
2023
Q1 		$14.3K Buy
+2,200
New +$16.9K ﹤0.01% 13319
2022
Q3 		– Sell
-88,000
Closed -$373K – 13555
2022
Q2 		$373K Buy
+88,000
New +$307K ﹤0.01% 9302

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors's SPRY Position: Q2 2026 in Review

Citadel Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 70% in Q2 2026, selling an estimated $10.7M and leaving 531,063 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #5012.

Citadel Advisors first reported a position in SPRY in Q4 2020 and has held it in 22 quarters since. The position peaked at $39.1M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Citadel Advisors held 531,063 shares of ARS Pharmaceuticals worth $4.25M as of Q2 2026.
  • Citadel Advisors sold 1,242,125 ARS Pharmaceuticals shares in Q2 2026, an estimated $10.7M.
  • ARS Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5012 holding.
  • Citadel Advisors first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's ARS Pharmaceuticals position peaked at $39.1M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.